CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
A Review of the Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Lean Body Mass in Humans
Jack Alistair Sargeant, Joseph Henson, James Adam King, Thomas Yates, Kamlesh Khunti, Melanie Jane Davies
Endocrinol Metab. 2019;34(3):247-262.   Published online September 26, 2019
DOI: https://doi.org/10.3803/EnM.2019.34.3.247

Excel Download

A Review of the Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Lean Body Mass in Humans
Endocrinology and Metabolism. 2019;34(3):247   Crossref logo
Link1 Link2 Link3

Evidence‐based comparison of glucagon‐like peptide receptor agonists and sodium–glucose cotransporter 2 inhibitors
Journal of Diabetes Investigation. 2019;11(1):17-19   Crossref logo
Link1 Link2 Link3

Glucagon-like Peptide-1 Receptor Agonists versus Sodium-Glucose Cotransporter Inhibitors for Treatment of T2DM
Journal of the Endocrine Society. 2020;4(5):   Crossref logo
Link1 Link2 Link3

PDB37 COST EFFECTIVENESS OF SODIUM-GLUCOSE COTRANSPORTER-2 (SGLT2) INHIBITORS, GLUCAGON-LIKE PEPTIDE 1 (GLP-1) RECEPTOR AGONISTS, DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS: A SYSTEMATIC REVIEW
Value in Health. 2019;22:S146   Crossref logo
Link1 Link2

Risk of fracture with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in real-world use: systematic review and meta-analysis of observational studies
Osteoporosis International. 2019;30(10):1923-1940   Crossref logo
Link1 Link2 Link3

Correction to: Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review
PharmacoEconomics. 2019;37(12):1553-1553   Crossref logo
Link1 Link2 Link3

Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review
PharmacoEconomics. 2019;   Crossref logo
Link1 Link2 Link3

The Effects of Hypoglycemic Agents on Non-alcoholic Fatty Liver Disease: Focused on Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists
Journal of Obesity & Metabolic Syndrome. 2019;28(1):18-29   Crossref logo
Link1 Link2

SUN-618 Decision Analysis for Glucagon-Like Peptide Receptor Agonists vs. Sodium-Glucose cotransporter2 Inhibitors in Type 2 Diabetes Mellitus
Journal of the Endocrine Society. 2020;4(Supplement_1):   Crossref logo
Link1 Link2

Glucagon-like peptide-1 receptor agonists or sodium–glucose cotransporter-2 inhibitors as add-on therapy for patients with type 2 diabetes? A systematic review and meta-analysis of surrogate metabolic endpoints
Diabetes & Metabolism. 2020;   Crossref logo
Link1 Link2